Navigation Links
HIV positive and HIV negative patients have similar survival rates following liver transplant
Date:4/24/2009

Copenhagen, Denmark, Friday 24 April: HIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.

The study results showed no difference in survival rates at 1 and 5 years between HIV negative and HIV positive patients (86.5% and 74% versus 87.1% and 78%, p=0.843), suggesting a good prognosis for HIV positive patients following liver transplant. However, the study confirmed that co-infection with hepatitis C virus (HCV) is a significant predictor of poorer survival rates in patients with HIV. Survival rates at 1 and 5 years were 73% and 53% in HIV positive patients with hepatitis C versus 87% and 69% (p=0.047) in HIV negative patients with hepatitis C.

Doctor Kosh Agarwal, of the Institute of Liver Studies, Kings College Hospital, London, who led the study said: "Data on long term outcomes from liver transplantation in HIV patients is limited. These study results are valuable confirmation that selected HIV positive patients are as suitable candidates for liver transplant as HIV negative patients and should have similar access to treatment. However, those patients with co-infection with hepatitis C did less well, emphasising the need for appropriate antiviral therapy early in the course of their HCV related liver disease. In the context of co-infection, these data emphasise the need to develop newer and more innovative treatment strategies. These should include exposure to new small molecule therapies for HCV that are currently being explored in mono-infection."

The researchers conducted a prospective analysis of the UK Transplant Database to determine the long-term outcomes in HIV patients undergoing liver transplant in the UK. They examined 6,315 adult patients (>18 years) undergoing their first liver transplant between March 1994 and April 2008. The patient groups compared in this analysis included:

  1. HIV positive patients who tested negative for both hepatitis C and hepatitis B
  2. HIV negative patients with hepatitis C
  3. HIV positive patients with hepatitis C

The three patient groups were comparable according to the Model End Stage Liver Disease (MELD) scores, which is a numerical scale to score disease severity and improve organ allocation in transplantation. HIV positive patients were younger compared to HIV negative patients (mean 42.2 years versus 51.2, p=0.001) and HIV positive patients co-infected with hepatitis C were younger (mean 39.9 years versus 51.8; p=0.0001) than HIV negative patients with hepatitis C.


'/>"/>

Contact: Camilla Dormer
easlpressoffice@cohnwolfe.com
44-078-761-90439
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. The ALS Association's 'ALS Across America' Focuses On Staying Positive and Involved
2. Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide
3. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
4. Economy Got You Down? Use The Principles Of Positive Psychology
5. Standard and Poors Raises Boston Scientifics Rating Outlook to Positive
6. Recent Industry Developments Reaffirm Positive Glucose Industry Outlook
7. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
8. Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures
9. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
10. Positive behavior support training curriculum
11. CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised ... five on the list of “ 5 US Cities with the Highest Plastic Rates .” ... and Miami. The results were calculated using a survey by RealSelf and ...
(Date:5/2/2016)... ... May 02, 2016 , ... MedaCheck, a leading medication ... outcomes, has announced its partnership with GrandView Health Services. , With decades of ... counter and prescription drug pharmacy services to thousands of residents. Serving Indiana, Ohio, ...
(Date:5/2/2016)... ... May 02, 2016 , ... The Evolve Paddle Board Company- which specializes ... today the outcome of their partnership with Yoloha Yoga- producers of high quality cork ... , SUP yoga has seen a dramatic rise in popularity throughout the last few ...
(Date:5/2/2016)... ... May 02, 2016 , ... One of Hollywood’s best kept ... Dermatology Surgery & Laser Center, in Milford, Penn. “Patients with busy lives want noninvasive ... fat treated and go home or back to work without having to wear recovery ...
(Date:5/2/2016)... Worcester, MA and Shelton, CT (PRWEB) , ... May 02, 2016 ... ... Scott Krug, President and Owner of New England Low Vision and Blindness (NELV&B) ... location will add more flexibility and convenience for people with vision impairments to get ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology: